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Abstract
Background: The Joint United Nations Programme on HIV/AIDS (UNAIDS) has developed an ambitious strategy to
end the AIDS epidemic. After eight years of antiretroviral therapy (ART) program we assessed progress towards the
UNAIDS 90–90-90 targets in Mbongolwane and Eshowe, KwaZulu-Natal, South Africa.
Methods: We conducted a cross-sectional household-based community survey using a two-stage stratified cluster
probability sampling strategy. Persons aged 15–59 years were eligible. We used face-to-face interviewer-administered
questionnaires to collect information on history of HIV testing and care. Rapid HIV testing was performed on site and
venous blood specimens collected from HIV-positive participants for antiretroviral drug presence test, CD4 count and
viral load. At the time of the survey the CD4 threshold for ART initiation was 350 cells/μL. We calculated progression
towards the 90–90-90 UNAIDS targets by estimating three proportions: HIV positive individuals who knew their status
(first 90), those diagnosed who were on ART (second 90), and those on ART who were virally suppressed (third 90).
Results: We included 5649/6688 (84.5%) individuals. Median age was 26 years (IQR: 19–40), 62.3% were women. HIV
prevalence was 25.2% (95% CI: 23.6–26.9): 30.9% (95% CI: 29.0–32.9) in women; 15.9% (95% CI: 14.0–18.0) in men. Overall
progress towards the 90–90-90 targets was as follows: 76.4% (95% CI: 74.1–78.6) knew their status, 69.9% (95% CI:
67.0–72.7) of those who knew their status were on ART and 93.1% (95% CI: 91.0–94.8) of those on ART were virally
suppressed. By sex, progress towards the 90–90-90 targets was: 79%–71%–93% among women; and 68%–68%–92%
among men (p-values of women and men comparisons were < 0.001, 0.443 and 0.584 respectively). By age, progress
was: 83%–75%–95% among individuals aged 30–59 years and 64%–58%–89% among those aged 15–29 years
(p-values of age groups comparisons were < 0.001, < 0.001 and 0.011 respectively).
Conclusions: In this context of high HIV prevalence, significant progress has been achieved with regards to
reaching the UNAIDS 90–90-90 targets. The third 90, viral suppression in people on ART, was achieved among
women and men. However, gaps persist in HIV diagnosis and ART coverage particularly in men and individuals younger
than 30 years. Achieving 90–90-90 is feasible but requires additional investment to reach youth and men.
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Background
The Joint United Nations Programme on HIV/AIDS
(UNAIDS) has developed the ambitious 90–90-90 strategy
with the objective to end the AIDS epidemic by 2030 by
achieving the following three targets: 90% of all people liv-
ing with HIV know their status; 90% of all people diagnosed
with HIV receive sustained antiretroviral therapy (ART);
and 90% of all people on ART are virally suppressed (73%
of all with HIV) [1].
The achievement of these targets and in general the
HIV cascade of care may be different in women and men
as well as in individuals belonging to different age groups
[2–5]. In addition, in the current context where test and
treat and follow-up of stable HIV-positive patients on
ART through viral load is recommended [6], some na-
tional programs have stopped systematic measurement of
CD4 counts in newly diagnosed HIV-positive patients and/
or during follow-up. Data from household-based studies on
the immunological status and viral load of HIV-positive in-
dividuals can be helpful to direct program activities and re-
sources towards underserved population groups [7].
South Africa is one of the countries with the HIV highest
prevalence in the world and KwaZulu-Natal (KZN) is the
province most affected by the epidemic, with an HIV preva-
lence of 27.9% in 2012 [8]. In 2005, the KZN Department
of Health (DOH) initiated an HIV program in the
Mbongolwane and Eshowe Health Service Areas, uMlalazi
Municipality, KZN province, which included HIV testing,
HIV care and ART initiation. In 2011, Médecins Sans
Frontières (MSF) started supporting this program with
large-scale HIV testing, training, mentoring and clinical
support in primary care clinics to improve coverage and
viral suppression.
In order to better understand the HIV epidemic at
local level and adapt the strategies of intervention we
assessed progress towards the UNAIDS 90–90-90 targets
in the overall population and by sex and age groups.
Methods
Design and population
We conducted a cross-sectional household-based com-
munity survey between July and October 2013.
A two-stage stratified cluster probability sampling
strategy was used for the selection of households accord-
ing to the 2011 Census [9]. In total, 125 clusters of 25
households each were selected from 14 administrative
units called Wards. Google Earth maps from 2011 with
exhaustive identification of the households were used to
sample the households to be visited by choosing randomly
the first household and then sequentially the closest to the
first/previous one. Field staff used Global Positioning
System (GPS) receivers to find the geographic coordi-
nates of each household.
People aged 15–59 years old living in Mbongolwane
and Eshowe Health Service Areas were eligible for enrol-
ment in the study. Those who signed a written informed
consent were included.
Study setting
Mbongolwane, a rural area, and Eshowe, the main town
of the municipality, account for approximately 120,000
inhabitants [9]. Decentralization of ART care to the per-
ipheral level was implemented gradually in this area. In
2011, the KZN province embraced the notion of nurse-
initiated and managed ART (NIM-ART). MSF support
to the KZN Department of Health (DOH) included pre-
vention activities such as condom distribution, voluntary
medical male circumcision, community mobilisation, large-
scale community-based HIV counselling and testing, imple-
mentation of point of care CD4 testing, linkage to care, and
training and mentoring of health staff in facilities in support
of NIM-ART. In 2013, two district hospitals and their
linked 10 primary healthcare facilities were ART-initiating
centres. The survey was conducted 8 years after the initi-
ation of the HIV program in the area. At the time of
the survey the CD4 threshold for ART initiation was
350 cells/μL.
Procedures
Prior to starting the survey, we conducted community
information and mobilization activities through several
channels: information on radio spots, meetings with com-
munity leaders and health facilities workers, information in
schools, leaflets and posters. In order to reach a maximum
of eligible individuals in their houses the survey teams
visited the houses from Tuesday to Sunday. Time slots
from early morning to late evening were covered in differ-
ent days of the week in order to maximize the possibilities
of finding the eligible participants at home. Due to the im-
portance that blood has in the Zulu culture, the survey
teams made a particular effort in explaining the purpose of
collecting and storing blood and the use of it. The survey
teams used face-to-face interviewer-administered question-
naires to collect information at the participant’s home on
socio-demographics and history of HIV testing and care
(see Additional files 1, 2 and 3). Questionnaires were devel-
oped for the Demographic and Health Surveys [10] and
adapted for the study. Certified lay counsellors performed
rapid HIV testing on site and provided pre and post-test
counselling to the participants willing to test at home.
Counsellors used Determine Rapid HIV-1/2 Antibody test
kit for screening, and if positive, Unigold Rapid HIV test kit
for confirmation according to the South African National
guidelines for HIV Counselling and Testing. The tests were
standardised and validated for this use. In addition, HIV-
positivity was confirmed by ELISA at the laboratory. Survey
nurses collected venous blood specimens from HIV-
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positive participants for antiretroviral (ARV) drug presence
test, CD4 count and viral load. Venous blood samples
were transported every evening to Global Clinical and
Viral Laboratory in Durban. CD4 count was performed
using a FACSCalibur™ device from Becton, Dickinson
and Company (BD) according to standard manufacturer’s
instructions on samples reported as HIV positive. Two dry
blood spots (DBS) samples were prepared using the venous
blood samples from each participant and transported in
batches to the Department of Pharmacology laboratory at
Groote Schuur Hospital, University of Cape Town, for ARV
drug levels. Qualitative testing for ARV drug levels was
performed for the presence of nevirapine, efavirenz and
lopinavir which covered all ARV regimens in use in the
public sector in the area. A liquid chromatography tandem
mass spectrometry assay with a limit of quantification of
0.04 μg/mL was used for all drugs. The assay was developed
and validated at the Division of Clinical Pharmacology,
University of Cape Town. Viral load was performed for
participants on ART for more than 6 months (deter-
mined by questionnaire) at Global Clinical and Viral
Laboratory in Durban using a NucliSens EasyQ HIV-
1v2.0 assay from Biomerieux according to manufac-
turer’s instructions. The test could quantify HIV-1 RNA
over the range of 20 copies to 20 million copies for
0.5 mL sample.
Data analyses
We calculated progression towards the 90–90-90 UNAIDS
targets by estimating three proportions: HIV positive indi-
viduals who knew their status (first 90), those diagnosed
who were on ART (second 90), and those on ART who
were virally suppressed (third 90). Viral suppression was
defined as having less than 1000 copies/mL. In addition, we
calculated five steps of the HIV cascade of care using the
total number of HIV positive individuals as a common
denominator. ‘Diagnosed’ were the individuals who knew
their HIV positive status prior to the survey; ‘Linked to
care’ were those who declared having sought care for their
HIV infection; ‘In care’ were those who were still receiving
HIV care at the time of the survey; ‘On ART’ were those
who had ARV detected in blood; ‘Virally suppressed’ were
those with viral load less below 1000 copies/mL. All statis-
tical analyses were adjusted for clustering at the level of
Ward and household. Descriptive analyses are presented
here with 95% confidence intervals (CI). Categorical vari-
ables were compared using proportional test. Analyses were
primarily performed using Stata 13 (™StataCorp, College
Station, Texas, USA).
Ethics
The protocol was approved by the University of Cape
Town Human Research Ethics Committee (HREC), the
Health Research Committee of the Health Research and
Knowledge Management Unit of KZN Department of
Health, and the Comité de Protection de Personnes de
Paris in France. All participants provided written informed
consent. Participants under 18 years provided assent and
their parents, guardians or caregivers provided written in-
formed consent for them.







n (%) n (%) n (%)
Age groups (years)
- 15–19 774 (22.0) 679 (31.9) 1453 (25.7)
- 20–24 623 (17.7) 436 (20.5) 1059 (18.8)
- 25–29 497 (14.1) 295 (13.8) 792 (14.0)
- 30–34 306 (8.7) 180 (8.5) 486 (8.6)
- 35–39 283 (8.0) 134 (6.3) 417 (7.4)
- 40–44 251 (7.1) 117 (5.5) 368 (6.5)
- 45–49 259 (7.4) 93 (4.4) 352 (6.2)
- 50–54 282 (8.0) 101 (4.7) 383 (6.8)
- 55–59 243 (6.9) 96 (4.5) 339 (6.0)
Marital Statusa
- Never Married 2448 (69.6) 178 (83.9) 4234 (75.0)
- Married/Living Together 905 (25.8) 294 (13.8) 1199 (21.2)
- Divorced/Separated 65 (1.9) 39 (1.8) 104 (1.8)
- Widowed 97 (2.8) 10 (0.5) 107 (1.9)
Educationb
- No schooling 319 (9.1) 112 (5.3) 431 (7.6)
- Primary 1448 (41.2) 963 (45.2) 2411 (42.7)
- Secondary 1625 (46.2) 988 (46.4) 2613 (46.3)
- Tertiary 126 (3.6) 67 (3.2) 193 (3.4)
Place residence
- Urban 246 (7.0) 143 (6.7) 389 (6.9)
- Semi urban 253 (7.2) 186 (8.7) 439 (7.8)
- Rural 2969 (84.4) 1742 (81.8) 4711 (83.4)
- Farm 50 (1.4) 60 (2.8) 110 (2.0)
Occupation
- Employed 671 (19.1) 567 (26.6) 1238 (21.9)
- Unemployed 1418 (40.3) 631 (29.6) 2049 (36.3)
- Housewife/husband 439 (12.5) 26 (1.2) 465 (8.2)
- Student 876 (24.9) 756 (35.5) 1632 (28.9)
- Other 114 (3.2) 151 (7.1) 265 (4.7)
Mobility
- Did not move 2957 (84.1) 1755 (82.4) 4712 (83.4)
- Moved residence or visitor 561 (16.0) 376 (17.6) 937 (16.6)
aInformation on marital status missing for 3 women and 2 men
bInformation on education missing for 1 man
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Results
Survey inclusions and participants
We visited 2377 households and we included 5649
(84.5%) participants among 6688 eligible individuals. In-
clusion rate was: 3518/4008 (87.8%) among women and
2131/2680 (79.5%) among men. The remaining individ-
uals were not included due to: refusal (8.7%), not being
at home (4.9%), being incapacitated (1.0%) and other
reasons (0.9%). The median age of the participants was
26 years (IQR: 19–40), 62.3% were women, 83.4% lived
in rural areas, 78.8% were not living with a partner,
49.7% had completed at least secondary school, 36.3%
declared no occupation and 16.6% had moved their resi-
dence in the 10 years prior to the survey or were visitors
(Table 1). Thirty-two per cent of the men were under
19 years, compared to 22% of the women, possibly
reflecting out-migration of adult men to seek work.
Reproductive health in women
In total, 2548 (72.4%) women had ever given birth. The
median number of children per women was 2 (IQR: 1–4).
At the time of the survey, 134 (3.8%) of the women were
pregnant and 308 (8.8%) were breastfeeding. Of the 1259
women who had delivered in the 5 years prior to the survey
(2008–2013), 1214 (96.4%) had had at least one medical
antenatal care (ANC) consultation, and 920 (73.1%) had
had 3 or more ANC consultations. The median number of
ANC consultations was 6 (IQR: 5–7). The median month
of pregnancy at the first ANC consultation was 4 months
(IQR: 3–5). Out of the 799 women who had delivered in
the 2 years prior to the survey, 745 (93.2%) had had an HIV
test as part of their ANC.
HIV-positive individuals
In total, 1423 participants were HIV positive. The overall
prevalence was 25.2% (95% CI: 23.6–26.9). Prevalence in
women was higher than in men: 30.9% (95% CI: 29.0–
32.9) vs 15.9% (95% CI: 14.0–18.0). Peak prevalence was
56.5% (95% CI: 50.9–62.0) in women at age 30–34 years
and 45.5% (95% CI 37.3–54.0) in men at age 35–39 years
(Fig. 1). Prevalence for age 15–29 years crudely averaged
22.3% (95% CI: 20.5–24.3) in women and 6.2% (95% CI:
5.1–7.6) in men, increasing dramatically from age 15 to
29 (3.9% to 55.0% in women and 1.5% to 26.7% in men).
HIV positive mothers who had delivered in the 5 years
prior to the study had a higher proportion of children
who had died than HIV negative mothers: 5.3% vs 2.5%
(p = 0.010). Of the 1400 HIV-positive participants with a
CD4 count, 130 (9.3%) had a CD4 count below 200
cells/μL, 255 (18.2%) between 200 and 349 cells/μL, 363
(25.9%) between 350 and 499 cells/μL and 652 (46.6%)
over or equal to 500 cells/μL. Median CD4 count was
483 cells/μL (IQR: 332–665). Among the 655 individuals
not on ART, 78 (11.9%) had a CD4 count below 200
cells/μL and 138 (21.1%) between 200 and 349 cells/μL.
Among the 741 individuals on ART, 52 (7.0%) had a
CD4 count below 200 cells/μL and 115 (15.5%) between
200 and 349 cells/μL. Of the participants with viral load
below 1000 copies/mL, 5.7% (95% CI: 4.2–7.5) had a
CD4 below 200 cells/μL and 19.7% (95% CI: 17.2–22.6)
a CD4 below 350 cells/μL (Table 2).
Progress towards 90–90-90 targets
UNAIDS targets were partially achieved with 76.4%
(95% CI: 74.1–78.6) of all HIV-positive who knew their
status, 69.9% (95% CI: 67.0–72.7) of them being on ART,
and 93.1% (95% CI: 91.0–94.8) of the people treated be-
ing virally suppressed (Fig. 2). Progress towards the first
target differed by sex and age. HIV diagnosis was: 79.0%
(95% CI: 76.4–81.4) in women versus 68.3% (95% CI:
63.1–73.1) in men (p < 0.001); and 83.3% (95% CI: 80.6–
85.7) in individuals aged 30–59 years versus 64.0% (95%
CI: 59.9–67.9) in those aged 15–29 years (p < 0.001).
Progress towards the second and third targets differed
by age but not by sex. ART among individuals diagnosed
was: 70.5% (95% CI: 67.7–73.2) in women versus 67.9%
(95% CI: 60.8–74.2) in men (p = 0.443); and 75.1% (95% CI:
Fig. 1 HIV prevalence by age and sex







ART ≥6 m & < 12 m
(N = 73)
n (%)









< 200 3 (2.8) 16 (10.7) 5 (6.8) 5 (5.2) 16 (4.3) 45 (5.7)
200–349 8 (7.6) 23 (15.4) 20 (27.4) 15 (15.5) 46 (12.4) 112 (14.1)
350–499 26 (24.5) 42 (28.2) 22 (30.1) 31 (32.0) 77 (20.8) 198 (24.9)
≥500 69 (65.1) 68 (45.6) 26 (35.6) 46 (47.4) 231 62.4) 440 (55.4)
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71.5–78.4) in individuals aged 30–59 years versus 57.6%
(95% CI: 51.8–63.2) in those aged 15–29 years (p < 0.001).
Viral suppression in individuals on ART was: 93.4% (95%
CI: 91.1–95.1) in women versus 92.1% (95% CI: 86.0–95.7)
in men (p = 0.584); and 94.5% (95% CI: 92.3–96.0) in indi-
viduals aged 30–59 years versus 89.0% (95% CI: 82.7–93.1)
in those aged 15–29 years (p = 0.011).
We also looked at other components of the cascade of
care and the proportions of ART and viral suppression
among all HIV-positive individuals. Of the 1384 HIV-
positive participants with complete information on HIV
diagnosis, ARV presence in blood and viral load, 71.0%
(95% CI: 68.6–73.4) were linked to care, 62.7% (95% CI:
59.8–65.6) were in care, 53.5% (95% CI: 50.6–56.3) were
on ART, 57.4% (95% CI: 54.6–60.1) were virally suppressed.
The largest gaps in the cascade of care occurred in men
and people aged 15–29 years (Table 3). Regarding viral
suppression, 60.3% (95% CI: 57.4–63.1) of all HIV-
positive women were virally suppressed compared to
47.9% (95% CI: 41.7–54.1) of the HIV-positive men and
66.2% (95% CI: 63.0–69.2) of the HIV-positive individuals
aged 30–59 years were virally suppressed compared to
41.3% (95% CI: 36.9–45.9) of those aged 15–29 years. Of
the 590 HIV-positive participants virally unsuppressed,
279 (47.3%) were undiagnosed and 260 (44.1%) were
diagnosed but not on ART. A breakdown by age and sex
is given in Fig. 3.
Discussion
In this area of KwaZulu-Natal, eight years into the public
ART program, of which two with MSF support, we found
that significant but insufficient progress towards the 90–
90-90 UNAIDS targets was achieved. Progress towards
the first and second targets was moderate and was par-
ticularly poor in men and individuals aged 15–29 years.
The third target was achieved (or very close to achieve-
ment) in all sex and age categories. This progress has been
made in a context of high HIV prevalence where one
quarter of the overall population is HIV positive.
These findings suggest that achieving the UNAIDS
2020 targets of 90–90-90 is feasible in South Africa, but
will require additional community-based investments in
testing and ART initiation especially among young people
and men. Investments to reach men may need to include
strategies to improve HIV knowledge [11]. A household-
based survey conducted in the 2 years following ours in
Botswana has reported a high coverage: 83.3% of individ-
uals knew their status, 87.4% of those were on ART, and
96.5% of those on ART had a viral load of 400 copies/mL
or less (70.2% of all people with HIV) in a context of high
HIV prevalence, 29% [4]. The early initiation and strong
political leadership of the ART programme in Botswana
might partially explain the relatively high ART coverage
achieved at a time when both South African and Botswana
guidelines recommended a CD4 threshold for ART initi-
ation of 350 cells/μL. However, a household-based survey
conducted the year following ours in another area of
KwaZulu-Natal, found lower rates of HIV-positivity
awareness (65% of the HIV-positive women and 52% of
the men), similar rates of ART among those who knew
their status (70% in women and 69% in men) and lower
rates of viral suppression (90% in women and 85% in
men) compared to our findings [3]. Other studies in KZN
have shown lower proportions of ART coverage among
HIV-positive individuals than ours [12–14] and at national
level only 33% of the HIV-positive individuals are on ART
and 24% are virally suppressed [15]. Similarly to others in
this context [13, 16–19], in the area surveyed the largest
Fig. 2 Progress towards 90–90-90 UNAIDS targets by sex and age
group. First 90: proportion of HIV-positive individuals who know their
status; Second 90: proportion of individuals on ART among those
who know their status; Third 90: proportion of individuals with
suppressed viral load among those on ART











% 95% CI % 95% CI % 95% CI % 95% CI % 95% CI
Diagnosed 79.0 76.4–81.4 68.3 63.1–73.1 64.0 59.9–67.9 83.3 80.6–85.7 76.4 74.1–78.6
Linked to care 74.3 71.6–76.9 60.4 54.2–66.1 57.2 53.0–61.3 78.6 75.6–81.3 71.0 68.6–73.4
In care 66.5 63.5–69.3 50.6 44.6–56.6 46.6 42.2–51.2 71.6 68.3–74.6 62.7 59.8–65.6
On ART 55.7 52.8–58.5 46.3 40.5–52.3 36.9 32.6–41.3 62.6 58.9–66.1 53.5 50.6–56.3
Viral load < 1000 60.3 57.4–63.1 47.9 41.7–54.1 41.3 36.9–45.9 66.2 63.0–69.2 57.4 54.6–60.1
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losses in the HIV cascade of care occurred on diagnosis
and on linkage from diagnosis into ART care. In addition,
the cascade in men and people 15–29 years of age showed
greater falls at each step [20, 21].
High incidence in the past associated with increased ac-
cess to ART [22–25], and other factors [26] may explain
the current picture of a very high prevalence. Prevalence
in women increased dramatically from 15 years with a
peak at 30–34 years. A rapid increase (though lower) was
also observed in men but with a lag of around 5 years of
age. Similar prevalence in women and men after 45 years
of age could be a reflection of a differential mortality by
age groups in the pre-ART era, a higher HIV incidence at
older ages in men compared to women, or other compet-
ing risks such as maternal mortality [24, 27–29]. The 2012
national survey found similar age/gender trends at na-
tional level [8]. Regarding the immunological status of the
people living with HIV, although the proportion in an ad-
vanced stage of HIV disease with CD4 below 200 cells/μL
was relatively low, the fact that more than half were not
on ART highlights that a non-negligible proportion of
people with HIV don’t access care or access it very late,
with significant risk of morbidity and mortality. These
findings support current recommendations that HIV pro-
grammes retain the capacity to perform CD4 cell count at
baseline and in case of treatment failure, as this remains
one of the best predictors of general patient wellness, dis-
ease progression and mortality risk [30]. They also support
the need for innovative strategies to reach individuals with
high barriers to HIV testing before they develop advanced
disease, such as self-testing and home-based testing.
Our study has some limitations. Some information, such
as HIV status awareness used in the cascade of care for
the identification of individuals already diagnosed and
linked to care, was self-reported, which may have led to
misclassifications. Otherwise, most of the results, crucially
including ART coverage, are based on laboratory data.
Conclusions
Significant progress has been achieved in this area with
regards to reaching the UNAIDS 90–90-90 targets. The
third 90, viral suppression in people on ART, was achieved
among women and men. However, further efforts on diag-
nosis and ART initiation are needed in order to reach the
first and second targets particularly in men and individ-
uals younger than 30 years. Indeed, almost half of the
people virally unsuppressed were undiagnosed. Achieving
90–90-90 is feasible but requires significant additional
investment.
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